Moderna's Flu Vaccine: mRNA-1010
The commercial brand name for Moderna's seasonal influenza vaccine (development code mRNA-1010) has not yet been publicly disclosed in the available evidence, as the vaccine is still referred to by its development designation in recent clinical trials and regulatory discussions.
Current Status and Development
mRNA-1010 is an investigational mRNA-based seasonal influenza vaccine that has completed Phase 3 clinical trials and demonstrated superior efficacy compared to standard-dose licensed influenza vaccines 1. The vaccine encodes hemagglutinin glycoproteins from WHO-recommended influenza strains and has shown:
- 26.6% relative vaccine efficacy (95% CI, 16.7 to 35.4) against RT-PCR-confirmed influenza-like illness in adults ≥50 years, meeting criteria for noninferiority, superiority, and higher-level superiority over standard comparators 1
- Robust immunogenicity across influenza A and B strains, with optimized compositions showing enhanced responses particularly against influenza B strains 2
- Acceptable safety profile, though with higher rates of solicited adverse reactions (injection-site pain 65.8%, fatigue 45.1%, headache 37.8%, myalgia 35.4%) compared to standard vaccines, with most reactions being mild to moderate and transient 1
Vaccine Composition
The trivalent formulation contains 37.5 μg total mRNA (12.5 μg encoding each strain's hemagglutinin) 1. The vaccine is manufactured without eggs or live influenza viruses, using mRNA technology similar to Moderna's COVID-19 vaccine platform 3.
Clinical Context
While the vaccine shows promise as a next-generation respiratory immunization platform with potential for combination formulations targeting influenza, SARS-CoV-2, and RSV 4, it remains under regulatory review. The commercial brand name will likely be announced upon FDA approval and market authorization.